Pharmacology Brochure Discussion
Pharmacology Brochure Discussion
Pharmacology Brochure Discussion
This brochure introduces a recent medication that was approved by the FDA but has not been in the market for long. It is a source of quick information but covers most of the essential areas of information that a nurse would need to have on their fingertips concerning the drug. Dayvigo is a sleeping pill that was approved in 2019, and whose effectiveness is quite high (FDA 2020). The drug is a lemborexant of the sedative-hypnotics class. It is an oral tablet whose dosage should not exceed 10mg. When co-administered with a CYP3A inhibitor, the dosage should be kept at only 5mg (Drugs.com, 2021). It is an effective medication for treating insomnia but can have serious side effects so it is essential for nurses to be well aware of its use, contraindications, side effects and other potential issues that could arise from its use.
The role of this brochure was to educate nurses on the existence and use of Dayvigo, an insomnia treatment medication that was recently introduced into the market. The brochure ought to offer all the critical information that nurses and pharmacists need to grasp promptly to effectively use the drug and achieve its full potential as an anti-insomnia medication. It is designed to offer detailed, verifiable and essential information on the drug to nurses and other users quickly and efficiently. It is not meant to be the definite primary education material on the drug, but a quick source of refreshing information on the drug. The brochure will be printed in an easily legible font and has a lot of information on most of the topics which a nurse would typically need to gather before issuing or when matching a patient to a prescription.
References
Drugs.com. (2021). Lemborexant. Day ago. Full Drug Information. https://www.drugs.com/mtm/lemborexant.html
Food and Drgug Administration (2020). Drug Approval Package- Dayvigo. https://www.google.com/search?q=DAyvigo+FDa&oq=DAyvigo+FDa&aqs=chrome..69i57j35i39l2j0i512l4j69i60.3636j1j7&sourceid=chrome&ie=UTF-8